查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球全基因組和EXOME定序市場：按產品、工作流程、應用、最終用戶、地區、競爭格局 - 分析和預測（2024-2033）
市場調查報告書
商品編碼
1558611

全球全基因組和EXOME定序市場：按產品、工作流程、應用、最終用戶、地區、競爭格局 - 分析和預測（2024-2033）

Global Whole Genome and Exome Sequencing Market: Focus on Product, Workflow, Application, End User, Region, and Competitive Landscape - Analysis and Forecast, 2024-2033
出版日期: | 出版商: BIS Research | 英文 106 Pages | 商品交期: 1-5個工作天內

價格

全基因組定序 (WGS) 和EXOME定序 (WES) 是尖端基因組技術，可對生物體的遺傳物質進行全面分析。

全基因定序對整個基因組進行定序，包括轉錄區和非編碼區，提供完整的遺傳藍圖。相較之下，WES 專注於僅對外顯子區域（基因組的蛋白質編碼部分，約佔基因組的 1-2%，但包含大多數已知的與疾病相關的變異）定序。這些技術為遺傳變異、疾病機制和演化生物學提供了前所未有的見解，徹底改變了基因組學。其應用範圍涵蓋臨床診斷、個人化醫療、腫瘤學和罕見疾病研究，大大推進了醫療保健和生物醫學研究。隨著技術的不斷改進、成本的降低和應用的擴展，WGS 和 WES 正在成為現代基因組學的重要工具。

主要市場統計數據
預測期 2024-2033
2024年評估 21.012 億美元
2033年預測 74.676 億美元
複合年成長率 15.13%

2023年，全球全基因組及EXOME定序市場規模達18.738億美元。預計到 2033 年，市場規模將達到 74.676 億美元，複合年成長率高達 15.13%，預計將大幅成長。這種激增反映出對個人化醫療的需求不斷成長以及全球遺傳疾病的盛行率不斷增加。基因檢測是精準醫療保健的重要組成部分，可以讓個人評估其對各種疾病的遺傳傾向，為患者和醫療保健提供者提供預防干涉和客製化治療策略的寶貴見解。隨著技術進步不斷提高基因檢測的準確性和可近性，這個市場有望徹底改變醫療保健服務，並在全球範圍內迎來預防性和個人化醫療的時代。

由於基因組技術的進步、定序成本的下降以及基因組資料在精準醫學、診斷和個人化醫療保健中的應用不斷擴大，全基因組和EXOME定序市場正在經歷快速成長。全基因組定序 (WGS) 可以全面洞察生物體的整個基因組成。相較之下，全EXOME定序(WES) 著重於基因的轉錄區，對於理解疾病機制至關重要。腫瘤學、罕見疾病診斷和藥物基因組學方面對基因檢測的需求不斷增加，基因組學研究投資的增加以及政府支持基因研究的有利舉措推動了該市場的發展。因此，WGS 和 WES 在臨床實踐中的整合變得越來越普遍，為創新醫療解決方案和改善患者治療結果鋪平了道路。

該報告考察了全球全基因組和EXOME定序市場，提供了市場概述、產品趨勢、工作流程、應用、最終用戶、區域以及參與市場的公司概況。

目錄

執行摘要

第1章 產業展望

第2章 全球全基因組和EXOME定序市場（依產品）

  • 概述
    • 套件
    • 裝置

第3章全球全基因組和EXOME定序市場（依工作流程）

  • 概述
    • 全基因組定序（WGS）
    • 全EXOME定序(WES)

第4章全球全基因組和EXOME定序市場（按應用）

  • 概述
    • 全基因組定序（WGS）
    • 全EXOME定序(WES)

第5章全球全基因組和EXOME定序市場（按最終用戶）

  • 概述
    • 製藥和生物技術公司
    • 診斷實驗室
    • 醫院和診所
    • 研究/學術機構
    • 其他

第6章 區域

  • 區域概況
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第7章市場－競爭基準化分析和公司概況

  • 關鍵策略和發展
  • 企業市場占有率分析
  • 公司簡介
    • Agilent Technologies, Inc.
    • BGI Group (Beijing Genomics Institute (BGI))
    • Bio-Rad Laboratories, Inc.
    • Eurofins Scientific SE
    • F. Hoffmann-La Roche Ltd
    • Illumina, Inc.
    • Laboratory Corporation of America Holdings
    • Novogene Corporation
    • Oxford Nanopore Technologies plc
    • Pacific Biosciences of California, Inc.
    • QIAGEN NV
    • Thermo Fisher Scientific, Inc.
    • ProPhase Labs, Inc.

第8章調查方法

Product Code: BHP1020SB

Introduction of Whole Genome and Exome Sequencing

Whole genome sequencing (WGS) and exome sequencing (WES) are cutting-edge genomic technologies that enable comprehensive analysis of an organism's genetic material. WGS involves sequencing the entire genome, encompassing both coding and non-coding regions, providing a complete genetic blueprint. In contrast, WES focuses on sequencing only the exonic regions, which are the protein-coding parts of the genome, representing about 1-2% of the genome but containing the majority of known disease-related variants. These technologies have revolutionized genomics by offering unprecedented insights into genetic variation, disease mechanisms, and evolutionary biology. Their applications span clinical diagnostics, personalized medicine, oncology, rare disease research, and more, driving significant advancements in healthcare and biomedical research. With continuous technological improvements, decreasing costs, and expanding applications, WGS and WES are becoming indispensable tools in modern genomics.

Market Introduction

KEY MARKET STATISTICS
Forecast Period2024 - 2033
2024 Evaluation$2,101.2 Million
2033 Forecast$7,467.6 Million
CAGR15.13%

The global whole genome and exome sequencing market, initially valued at $1,873.8 million in 2023, is poised for substantial growth, projected to reach $7,467.6 million by 2033, marking a remarkable compound annual growth rate (CAGR) of 15.13%. This surge reflects the escalating demand for personalized medicine and the increasing prevalence of genetic disorders worldwide. Hereditary genetic testing, a pivotal component of precision healthcare, enables individuals to assess their genetic predispositions to various diseases, empowering them and healthcare providers with invaluable insights for proactive intervention and tailored treatment strategies. As advancements in technology continue to enhance the accuracy and accessibility of genetic testing, the market is primed to revolutionize healthcare delivery, ushering in an era of preventive and personalized medicine on a global scale.

The whole genome and exome sequencing market has been experiencing rapid growth driven by advancements in genomic technologies, decreasing sequencing costs, and the expanding applications of genomic data in precision medicine, diagnostics, and personalized healthcare. Whole genome sequencing (WGS) provides comprehensive insights into the entire genetic makeup of an organism. In contrast, whole exome sequencing (WES) focuses on the coding regions of genes, which are crucial for understanding disease mechanisms. The market has been fueled by increasing demand for genetic testing in oncology, rare disease diagnosis, pharmacogenomics, rising investments in genomics research, and favorable government initiatives supporting genetic research. As a result, the integration of WGS and WES in clinical practice is becoming more prevalent, paving the way for innovative healthcare solutions and improved patient outcomes.

Industrial Impact

The industrial impact of the whole genome and exome sequencing market has been profound, significantly influencing various sectors, including healthcare, pharmaceuticals, biotechnology, and research. In healthcare, the adoption of these sequencing technologies has been transforming diagnostics and treatment strategies by enabling precise identification of genetic mutations and tailored therapeutic interventions. This precision medicine approach not only enhances patient care but also reduces healthcare costs by minimizing trial-and-error treatments. In the pharmaceutical industry, whole genome and exome sequencing have been pivotal in drug discovery and development, allowing for the identification of novel drug targets and biomarkers, thereby accelerating the development of targeted therapies. Biotechnology companies are leveraging these technologies to advance research in gene editing, synthetic biology, and agricultural biotechnology, leading to innovations in crop improvement and sustainable agriculture. Moreover, the increasing use of sequencing in academic and clinical research has been driving scientific discoveries and expanding one's understanding of genetic diseases and human biology. Overall, the integration of whole genome and exome sequencing across these industries is fostering innovation, improving efficiency, and opening new avenues for economic growth and development.

Market Segmentation

Segmentation 1: by Product

  • Kits
    • Target Enrichment Kits
    • Library Preparation Kits
    • Sequencing Kits
  • Instruments

In the global whole genome and exome sequencing market, as of 2023, the kits segment holds the largest share at 62.83%. This dominance can be attributed to the essential role kits play in the sequencing process, encompassing DNA extraction, library preparation, and target enrichment, which are crucial for accurate and efficient sequencing. Kits are widely adopted due to their ease of use, reliability, and cost-effectiveness, streamlining laboratory workflows and ensuring consistent results. This rapid growth is expected to be driven by the increasing need for advanced bioinformatics tools and data analysis services to handle the vast amounts of data generated by sequencing technologies. Software solutions enhance data management, interpretation, and visualization, while services provide technical support, training, and consultancy, making sequencing data more accessible and actionable for clinical and research applications.

Segmentation 2: by Workflow

  • Whole Genome Sequencing (WGS)
    • Sample Extraction/Isolation/Purification
    • Library Preparation
    • Library Quantification
    • Analysis (Bioinformatics)
  • Whole Exome Sequencing (WES)
    • Sample Extraction/Isolation/Purification
    • Library Preparation
    • Library Quantification
    • Target Enrichment
    • Analysis (Bioinformatics)

Based on workflow, the global whole genome and exome market was led by the WES segment, which held a 64.92% share in 2023. The whole exome sequencing (WES) workflow begins with the extraction, isolation, and purification of DNA from biological samples such as blood or saliva. This is followed by library preparation, where the DNA is fragmented and adaptors are added, and library quantification to ensure accurate DNA concentration. Next, target enrichment involves hybridizing the DNA library with probes that capture the exonic regions, enriching these target sequences. The enriched library is then sequenced using next-generation sequencing (NGS) technology. The resulting data undergoes bioinformatics analysis, where it is aligned to a reference genome, and genetic variations are identified, annotated, and interpreted for their potential impact on gene function and disease association.

Segmentation 3: by Application

  • Whole Genome Sequencing (WGS)
    • Oncology
    • Microbial
    • Non-Invasive Prenatal Testing (NIPT)
    • Others
  • Whole Exome Sequencing (WES)
    • Oncology
    • Rare Disease
    • Gene Discovery
    • Others

Segmentation 4: by End User

  • Pharmaceutical and Biotechnology Companies
  • Diagnostic Laboratories
  • Hospitals and Clinics
  • Research and Academic Institutes
  • Others

In the global whole genome and exome sequencing (WGS and WES) market, as of 2023, the research and academic institutes segment holds the largest share at 39.69%, driven by extensive use in genomic research, significant government funding, and collaborative projects that advance scientific understanding of genetic diseases.

Segmentation 5: by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Netherlands
    • Rest-of-Europe
  • Asia-Pacific
    • Japan
    • India
    • China
    • Singapore
    • Australia
    • Rest-of-Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest-of-Latin America
  • Middle East and Africa
    • South Africa
    • U.A.E.
    • Rest-of-Middle East and Africa

The whole genome and exome market in the North America region is expected to witness a significant growth rate of 14.80% during the forecast period, marked by the increasing prevalence of genetic disorders and the growing demand for personalized medicine and robust government initiatives. However, the Asia-Pacific region is expected to reach $1,784.8 million in 2033 from $372.9 million in 2023, at a CAGR of 17.26% during the forecast period 2024-2033.

Recent Developments in the Whole Genome and Exome Market

  • In April 2024, Eurofins Genomics AgriGenomics Europe, a leading provider of DNA sequencing and genotyping services, partnered with Gencove, a pioneer in low-pass whole genome sequencing (lpWGS) imputation and analysis. This collaboration offers a comprehensive lpWGS solution in Europe, combining Gencove's data analytics platform with Eurofins' sequencing capabilities for high-throughput, cost-effective genotyping.
  • In April 2024, Labcorp, a global leader in laboratory services, launched Labcorp Plasma Detect, the first clinically validated, tumor-informed, whole-genome sequencing circulating tumor DNA (ctDNA) molecular residual disease (MRD) solution. This test has been designed for early-stage colon cancer to identify patients at increased risk of recurrence post-surgery or adjuvant chemotherapy (ACT).
  • In March 2024, Bayer AG and Thermo Fisher Scientific partnered to develop NGS-based companion diagnostic assays (CDx) to identify patients suitable for Bayer's precision cancer therapies, enabling decentralized genomic testing with rapid results.
  • In March 2024, MGI Tech announced a milestone collaboration with Eurofins Genomics Europe Genotyping A/S, marking the first corporate order of the revolutionary DNBSEQ-T20X2 ("T20") ultra-high throughput sequencer in Europe. This order, which includes the ZTRON Appliance and various MGI lab automation products, signifies a significant advancement in precision health initiatives across the continent.
  • In January 2024, Eurofins Genomics, a global leader in sequencing services, announced the opening of a new certified sequencing lab in Bothell, Washington, serving the greater Seattle area. This facility leverages Oxford Nanopore's sequencing platform to deliver results within 12 hours from sample pickup. Eurofins Genomics has partnered with 30 local labs in Seattle, conducting daily sample pickups and sequencing for the biotech hub.

Demand - Drivers, Challenges, and Opportunities

Market Demand Drivers:

Growing Applications of Whole Genome and Exome Sequencing in Clinical Diagnostics: The increasing clinical applications of whole genome sequencing (WGS) and whole exome sequencing (WES) are significantly influencing the overall sequencing market. The adoption of WGS in clinical diagnostics for rare diseases is providing a more comprehensive genetic analysis compared to traditional methods. According to a study, "Whole Exome and Genome Sequencing in Mendelian Disorders: A Diagnostic and Health Economic Analysis," published in Nature Journal in August 2022, WGS can detect a broader range of genetic variants, including those in non-coding regions, which are often missed by WES. This comprehensive detection capability improves diagnostic accuracy, thereby enhancing patient care and outcomes.

Market Challenges:

Privacy and Ethical Concerns due to Increased Risk of Security Breaches: Ethical concerns related to privacy, confidentiality, and the return of results are prominent in the context of sequencing and must be addressed during the informed consent process. The method of data storage is crucial in managing privacy risks for participants. Privacy and ethical concerns have become significant challenges in the whole genome and exome sequencing market, especially with the increasing risk of security breaches.

Market Opportunities:

Increasing Usage of Sequencing Methodologies in Emerging Markets: The increasing application of whole genome and whole exome sequencing in developing countries presents a significant growth opportunity for the global market. As these technologies become more affordable and accessible, they are being integrated into healthcare systems in regions that were previously limited by cost and infrastructure. The availability of these advanced sequencing methods allows for the precise diagnosis and treatment of genetic diseases, which can significantly improve healthcare outcomes in these regions. This integration is facilitated by international collaborations and support from global health initiatives, which aim to enhance the capabilities of local healthcare providers.

How can this report add value to an organization?

Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements and emerging applications in genome and exome sequencing, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.

Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.

Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors' strengths and weaknesses and allowing them to strategize effectively to gain a competitive edge in the market.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

  • The base year considered for the calculation of the market size is 2023. A historical year analysis has been done for the period FY2021-FY2022. The market size has been estimated for FY2023 and projected for the period FY2024-FY2033.
  • The scope of this report has been carefully derived based on interactions with experts in different companies across the world. This report provides a market study of upstream and downstream products of whole genome and exome.
  • The market contribution of the whole genome and exome technologies anticipated to be launched in the future has been calculated based on the historical analysis of the solutions.
  • Revenues of the companies have been referenced from their annual reports for FY2022 and FY2023. For private companies, revenues have been estimated based on factors such as inputs obtained from primary research, funding history, market collaborations, and operational history.
  • The market has been mapped based on the available whole genome and exome solutions. All the key companies with significant offerings in this field have been considered and profiled in this report.

Primary Research:

The primary sources involve industry experts in whole genome and exome, including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

  • Validation and triangulation of all the numbers and graphs
  • Validation of the report's segmentation and key qualitative findings
  • Understanding the competitive landscape and business model
  • Current and proposed production values of a product by market players
  • Validation of the numbers of the different segments of the market in focus
  • Percentage split of individual markets for regional analysis

Secondary Research

Open Sources

  • Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
  • Annual reports, SEC filings, and investor presentations of the leading market players
  • Company websites and detailed study of their product portfolio
  • Gold standard magazines, journals, white papers, press releases, and news articles
  • Paid databases

The key data points taken from the secondary sources include:

  • Segmentations and percentage shares
  • Data for market value
  • Key industry trends of the top players of the market
  • Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
  • Quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

Profiled companies have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

In 2023, Illumina, Inc. held major share of the whole genome and exome sequencing market, reflecting its leading position and extensive portfolio of advanced sequencing technologies. Thermo Fisher Scientific Inc., Qiagen N.V., Pacific Biosciences (PacBio) and Oxford Nanopore Technologies plc are the other major players with, leveraging its broad range of genomic solutions and strong market presence. The companies are recognized for their innovative sequencing technologies that provide unique capabilities in long-read sequencing and real-time analysis. The competitive landscape, with Illumina leading significantly while other key players continue to innovate and capture niche segments within the market.

Some prominent names established in this market are:

  • Agilent Technologies, Inc.
  • BGI Group
  • Bio-Rad Laboratories, Inc
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings
  • Novogene Corporation
  • Oxford Nanopore Technologies plc
  • Pacific Biosciences of California, Inc.
  • QIAGEN N.V.
  • Thermo Fisher Scientific Inc.
  • Gene by Gene, Ltd.
  • ProPhase Labs, Inc.

Table of Contents

Executive Summary

Scope and Definition

1 Industry Outlook

  • 1.1 Market Trends
    • 1.1.1 Technological Innovations in the Sequencing Technology
    • 1.1.2 Numerous Inorganic Growth Activities in the Market
  • 1.2 COVID-19 Impact on Market
  • 1.3 Regulatory Framework
    • 1.3.1 Legal Requirements and Framework in the U.S.
    • 1.3.2 Legal Requirements and Framework in Europe
    • 1.3.3 Legal Requirements and Framework in Japan
  • 1.4 Supply Chain Analysis
  • 1.5 Market Dynamics Overview
    • 1.5.1 Market Drivers
      • 1.5.1.1 Growing Applications of Whole Genome and Exome Sequencing in Clinical Diagnostics
      • 1.5.1.2 Rising Demand for Personalized Medicine Influencing the Demand for Whole Genome and Exome Sequencing
      • 1.5.1.3 Lowering Costs and Increasing Accessibility of Genome Sequencing
      • 1.5.1.4 Ongoing Whole Genome Sequencing Government Initiatives around the World
    • 1.5.2 Market Restraints
      • 1.5.2.1 Privacy and Ethical Concerns due to Increased Risk of Security Breaches
    • 1.5.3 Market Opportunities
      • 1.5.3.1 Increasing Usage of Sequencing Technology in Emerging Markets

2 Global Whole Genome and Exome Sequencing Market (by Product)

  • 2.1 Overview
    • 2.1.1 Kits
      • 2.1.1.1 Target Enrichment Kits
      • 2.1.1.2 Library Preparation Kits
      • 2.1.1.3 Sequencing Kits
    • 2.1.2 Instruments

3 Global Whole Genome and Exome Sequencing Market (by Workflow)

  • 3.1 Overview
    • 3.1.1 Whole Genome Sequencing (WGS)
      • 3.1.1.1 Sample Extraction/Isolation/Purification
      • 3.1.1.2 Library Preparation
      • 3.1.1.3 Library Quantification
      • 3.1.1.4 Analysis (Bioinformatics)
    • 3.1.2 Whole Exome Sequencing (WES)
      • 3.1.2.1 Sample Extraction/Isolation/Purification
      • 3.1.2.2 Library Preparation
      • 3.1.2.3 Library Quantification
      • 3.1.2.4 Target Enrichment
      • 3.1.2.5 Analysis (Bioinformatics)

4 Global Whole Genome and Exome Sequencing Market (by Application)

  • 4.1 Overview
    • 4.1.1 Whole Genome Sequencing (WGS)
      • 4.1.1.1 Oncology
      • 4.1.1.2 Microbial
      • 4.1.1.3 Non-Invasive Prenatal Testing (NIPT)
      • 4.1.1.4 Others
    • 4.1.2 Whole Exome Sequencing (WES)
      • 4.1.2.1 Oncology
      • 4.1.2.2 Rare Disease
      • 4.1.2.3 Gene Discovery
      • 4.1.2.4 Others

5 Global Whole Genome and Exome Sequencing Market (by End User)

  • 5.1 Overview
    • 5.1.1 Pharmaceutical and Biotechnology Companies
    • 5.1.2 Diagnostic Laboratories
    • 5.1.3 Hospitals and Clinics
    • 5.1.4 Research and Academic Institutes
    • 5.1.5 Others

6 Region

  • 6.1 Regional Summary
  • 6.2 North America
    • 6.2.1 Regional Overview
    • 6.2.2 Driving Factors for Market Growth
    • 6.2.3 Factors Challenging the Market
      • 6.2.3.1 By End User
    • 6.2.4 U.S.
    • 6.2.5 Canada
  • 6.3 Europe
    • 6.3.1 Regional Overview
    • 6.3.2 Driving Factors for Market Growth
    • 6.3.3 Factors Challenging the Market
      • 6.3.3.1 By End User
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 U.K.
    • 6.3.7 Spain
    • 6.3.8 Italy
    • 6.3.9 Netherlands
    • 6.3.10 Rest-of-Europe
  • 6.4 Asia-Pacific
    • 6.4.1 Regional Overview
    • 6.4.2 Driving Factors for Market Growth
    • 6.4.3 Factors Challenging the Market
      • 6.4.3.1 By End User
    • 6.4.4 China
    • 6.4.5 India
    • 6.4.6 Australia
    • 6.4.7 Japan
    • 6.4.8 Singapore
    • 6.4.9 Rest-of-Asia-Pacific
  • 6.5 Latin America
    • 6.5.1 Regional Overview
    • 6.5.2 Driving Factors for Market Growth
    • 6.5.3 Factors Challenging the Market
      • 6.5.3.1 By End User
    • 6.5.4 Brazil
    • 6.5.5 Mexico
    • 6.5.6 Rest-of-Latin America
  • 6.6 Middle East and Africa
    • 6.6.1 Regional Overview
    • 6.6.2 Driving Factors for Market Growth
    • 6.6.3 Factors Challenging the Market
      • 6.6.3.1 By End User
    • 6.6.4 U.A.E.
    • 6.6.5 South Africa
    • 6.6.6 Rest-of-Middle East and Africa

7 Markets - Competitive Benchmarking & Company Profiles

  • 7.1 Key Strategies and Development
  • 7.2 Company Share Analysis
  • 7.3 Company Profiles
    • 7.3.1 Agilent Technologies, Inc.
      • 7.3.1.1 Overview
      • 7.3.1.2 Top Products/Product Portfolio
      • 7.3.1.3 Top Competitors
      • 7.3.1.4 Key Personnel
      • 7.3.1.5 Analyst View
    • 7.3.2 BGI Group (Beijing Genomics Institute (BGI))
      • 7.3.2.1 Overview
      • 7.3.2.2 Top Products
      • 7.3.2.3 Top Competitors
      • 7.3.2.4 Key Personnel
      • 7.3.2.5 Analyst View
    • 7.3.3 Bio-Rad Laboratories, Inc.
      • 7.3.3.1 Overview
      • 7.3.3.2 Top Products/Product Portfolio
      • 7.3.3.3 Top Competitors
      • 7.3.3.4 Key Personnel
      • 7.3.3.5 Analyst View
    • 7.3.4 Eurofins Scientific SE
      • 7.3.4.1 Overview
      • 7.3.4.2 Top Products
      • 7.3.4.3 Top Competitors
      • 7.3.4.4 Key Personnel
      • 7.3.4.5 Analyst View
    • 7.3.5 F. Hoffmann-La Roche Ltd
      • 7.3.5.1 Overview
      • 7.3.5.2 Top Products
      • 7.3.5.3 Top Competitors
      • 7.3.5.4 Key Personnel
      • 7.3.5.5 Analyst View
    • 7.3.6 Illumina, Inc.
      • 7.3.6.1 Overview
      • 7.3.6.2 Top Products/Product Portfolio
      • 7.3.6.3 Top Competitors
      • 7.3.6.4 Key Personnel
      • 7.3.6.5 Analyst View
    • 7.3.7 Laboratory Corporation of America Holdings
      • 7.3.7.1 Overview
      • 7.3.7.2 Top Products/Product Portfolio
      • 7.3.7.3 Top Competitors
      • 7.3.7.4 Key Personnel
      • 7.3.7.5 Analyst View
    • 7.3.8 Novogene Corporation
      • 7.3.8.1 Overview
      • 7.3.8.2 Top Products/Product Portfolio
      • 7.3.8.3 Top Competitors
      • 7.3.8.4 Key Personnel
      • 7.3.8.5 Analyst View
    • 7.3.9 Oxford Nanopore Technologies plc
      • 7.3.9.1 Overview
      • 7.3.9.2 Top Products
      • 7.3.9.3 Top Competitors
      • 7.3.9.4 Key Personnel
      • 7.3.9.5 Analyst View
    • 7.3.10 Pacific Biosciences of California, Inc.
      • 7.3.10.1 Overview
      • 7.3.10.2 Top Products
      • 7.3.10.3 Top Competitors
      • 7.3.10.4 Key Personnel
      • 7.3.10.5 Analyst View
    • 7.3.11 QIAGEN N.V.
      • 7.3.11.1 Overview
      • 7.3.11.2 Top Products
      • 7.3.11.3 Top Competitors
      • 7.3.11.4 Key Personnel
      • 7.3.11.5 Analyst View
    • 7.3.12 Thermo Fisher Scientific, Inc.
      • 7.3.12.1 Overview
      • 7.3.12.2 Top Products
      • 7.3.12.3 Top Competitors
      • 7.3.12.4 Key Personnel
      • 7.3.12.5 Analyst View
    • 7.3.13 ProPhase Labs, Inc.
      • 7.3.13.1 Overview
      • 7.3.13.2 Top Products
      • 7.3.13.3 Top Competitors
      • 7.3.13.4 Key Personnel
      • 7.3.13.5 Analyst View

8 Research Methodology

  • 8.1 Data Sources
    • 8.1.1 Primary Data Sources
    • 8.1.2 Secondary Data Sources
    • 8.1.3 Data Triangulation
  • 8.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Global Whole Genome and Exome Sequencing Market (by Region), $Million, 2023, 2026, and 2033
  • Figure 2: Global Whole Genome and Exome Sequencing Market (by Product), $Million, 2023, 2026, and 2033
  • Figure 3: Global Whole Genome and Exome Sequencing Market (by End User), $Million, 2023, 2026, and 2033
  • Figure 4: Key Events to Keep Track of within the Whole Genome and Exome Sequencing Market
  • Figure 5: Value and Supply Chain Analysis, Global Whole Genome and Exome Sequencing Market
  • Figure 6: Analysis of Market Navigating Factors, 2023-2033
  • Figure 7: Key Clinical Applications of Whole Genome and Whole Exome Sequencing
  • Figure 8: Number of Research Papers Mentioning Personalized Medicine in PubMed, 2010-2023
  • Figure 9: Decreasing Genome Sequencing Costs
  • Figure 10: Map of a Few Recent and Ongoing Government-Funded National Genomic-Medicine Initiatives
  • Figure 11: Examples of Security Breaches in Whole Genome and Exome Sequencing
  • Figure 12: U.S. Whole Genome and Exome Sequencing Market, $Million, 2023-2033
  • Figure 13: Canada Whole Genome and Exome Sequencing Market, $Million, 2023-2033
  • Figure 14: France Whole Genome and Exome Sequencing Market, $Million, 2023-2033
  • Figure 15: Germany Whole Genome and Exome Sequencing Market, $Million, 2023-2033
  • Figure 16: U.K. Whole Genome and Exome Sequencing Market, $Million, 2023-2033
  • Figure 17: Spain Whole Genome and Exome Sequencing Market, $Million, 2023-2033
  • Figure 18: Italy Whole Genome and Exome Sequencing Market, $Million, 2023-2033
  • Figure 19: Netherlands Whole Genome and Exome Sequencing Market, $Million, 2023-2033
  • Figure 20: Rest-of-Europe Whole Genome and Exome Sequencing Market, $Million, 2023-2033
  • Figure 21: China Whole Genome and Exome Sequencing Market, $Million, 2023-2033
  • Figure 22: India Whole Genome and Exome Sequencing Market, $Million, 2023-2033
  • Figure 23: Australia Whole Genome and Exome Sequencing Market, $Million, 2023-2033
  • Figure 24: Japan Whole Genome and Exome Sequencing Market, $Million, 2023-2033
  • Figure 25: Singapore Whole Genome and Exome Sequencing Market, $Million, 2023-2033
  • Figure 26: Rest-of-Asia-Pacific Whole Genome and Exome Sequencing Market, $Million, 2023-2033
  • Figure 27: Brazil Whole Genome and Exome Sequencing Market, $Million, 2023-2033
  • Figure 28: Mexico Whole Genome and Exome Sequencing Market, $Million, 2023-2033
  • Figure 29: Rest-of-Latin America Whole Genome and Exome Sequencing Market, $Million, 2023-2033
  • Figure 30: U.A.E. Whole Genome and Exome Sequencing Market, $Million, 2023-2033
  • Figure 31: South Africa Whole Genome and Exome Sequencing Market, $Million, 2023-2033
  • Figure 32: Rest-of-Middle East and Africa Whole Genome and Exome Sequencing Market, $Million, 2023-2033
  • Figure 33: Strategic Initiatives, January 2021-April 2024
  • Figure 34: Share of Strategic Initiatives, January 2021-April 2024
  • Figure 35: Global Whole Genome and Exome Sequencing Market, Company Revenue Share Analysis, 2023
  • Figure 36: Data Triangulation
  • Figure 37: Top-Down and Bottom-Up Approach
  • Figure 38: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Opportunities across Regions
  • Table 3: Recent Technological Innovations
  • Table 4: Few Major Inorganic Growth Activities in the Whole Genome and Exome Sequencing Market
  • Table 5: Global Whole Genome and Exome Sequencing Market (by Product), $Million, 2023-2033
  • Table 6: Global Whole Genome and Exome Sequencing Market (by Kits), $Million, 2023-2033
  • Table 7: Global Whole Genome Sequencing Market (by Workflow), $Million, 2023-2033
  • Table 8: Global Whole Exome Sequencing Market (by Workflow), $Million, 2023-2033
  • Table 9: Global Whole Genome Sequencing Market (by Application), $Million, 2023-2033
  • Table 10: Global Whole Exome Sequencing Market (by Application), $Million, 2023-2033
  • Table 11: Global Whole Genome and Exome Sequencing Market (by End User), $Million, 2023-2033
  • Table 12: Global Whole Genome and Exome Sequencing Market (by Region), $Million, 2023-2033
  • Table 13: North America Whole Genome and Exome Sequencing Market (by End User), $Million, 2023-2033
  • Table 14: Europe Whole Genome and Exome Sequencing Market (by End User), $Million, 2023-2033
  • Table 15: Asia-Pacific Whole Genome and Exome Sequencing Market (by End User), $Million, 2023-2033
  • Table 16: Latin America Whole Genome and Exome Sequencing Market (by End User), $Million, 2023-2033
  • Table 17: Middle East and Africa Whole Genome and Exome Sequencing Market (by End User), $Million, 2023-2033